Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.57 |
| ▸ | RXRA | P19793 | 5/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | DRD1 | P21728 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.51 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.51 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.51 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.51 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.51 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.51 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6347483 | 1.00 | PPARG (0.57) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL6347478 | 1.00 | PPARG (0.57) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL6936351 | 0.90 | PPARG (0.71) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL6938658 | 0.90 | PPARG (0.71) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL6936353 | 0.90 | PPARG (0.71) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL6934000 | 0.89 | PPARG (0.57) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL8158484 | 0.89 | PPARG (0.57) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL8149960 | 0.89 | PPARG (0.57) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL8149959 | 0.89 | PPARG (0.57) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL8158481 | 0.89 | PPARG (0.57) | PPARGRXRACYP1A2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050244914-A1 | Methods for identifying compounds for inhibition of neoplastic lesions, and pharmaceutical compositions containing such compounds | LIU LI | 2005-11-03 | — | — | US | disclosed |
| US-6875575-B1 | Diagnostic methods for neoplasia | OSI PHARMACEUTICALS, INC. (US) | 2005-04-05 | — | — | US | disclosed |
| US-6869944-B2 | Method for treating a patient with neoplasia by treatment with a platinum coordination complex | OSI PHARMACEUTICALS, INC. (US) | 2005-03-22 | — | — | US | disclosed |
| US-20040009464-A1 | Methods for identifying compounds for inhibition of neoplastic lesions, and pharmacetical compositions containing such compounds | OSI PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| US-20030220252-A1 | Method for treating a patient with neoplasia by treatment with a gonadotropin releasing hormone analog | OSI PHARMACEUTICALS, INC. | 2003-11-27 | — | — | US | disclosed |
| US-20030190686-A1 | Methods for identifying compounds for inhibition of neoplastic lesions, and pharmacetical compositions containing such compounds | OSI PHARMACEUTICALS, INC. | 2003-10-09 | — | — | US | disclosed |
| US-20030175833-A1 | Packaged pharmaceuticals and methods for causing compounds and pharmaceutical compositions to be used as inhibitors of neoplastic lesions | OSI PHARMACEUTICALS, INC. | 2003-09-18 | — | — | US | disclosed |
| US-20030130210-A1 | Method for treating a patient with neoplasia by treatment with an anthracycline antibiotic | OSI PHARMACEUTICALS, INC. | 2003-07-10 | — | — | US | disclosed |
| US-20030113382-A1 | Method for treating a patient with neoplasia by treatment with a platinum coordination complex | OSI PHARMACEUTICALS, INC. | 2003-06-19 | — | — | US | disclosed |
| US-20030109418-A1 | Methods for identifying compounds for inhibition of neoplastic lesions, and pharmaceutical compositions containing such compounds | OSI PHARMACEUTICALS, INC. | 2003-06-12 | — | — | US | disclosed |
| US-20010012858-A1 | Method for treating a patient with neoplasia by treatment with a platinum coordination complex | OSI PHARMACEUTICALS, INC. | 2001-08-09 | — | — | US | disclosed |
| US-6235776-B1 | ADMINISTERING WITH PHOSPHODIESTERASE INHIBITOR | CELL PATHWAYS, INC. | 2001-05-22 | — | — | US | disclosed |
| US-6235782-B1 | SYNERGISTIC MIXTURE WITH PHOSPHODIESTERASE INHIBITOR; SIDE EFFECT REDUCTION | OSI PHARMACEUTICALS, INC. | 2001-05-22 | — | — | US | disclosed |
| EP-0881300-B1 | Method for identifying compounds for inhibition of neoplastic lesions | CELL PATHWAYS INC (US) | 2001-01-17 | — | — | EP | disclosed |
| US-6156528-A | Methods for using a phosphodiesterase in pharmaceutical screening to identify compounds for treatment of neoplasia | CELL PATHWAYS, INC (US) | 2000-12-05 | — | — | US | disclosed |
| US-6130053-A | ACCURATE METHOD FOR SCREENING SELECTIVE APOPTOTIC ANTINEOPLASTIC DRUGS BY SELECTING COMPOUND WHICH HAS ANTINEOPLASTIC ACTIVITY AND INCREASES PROTEIN KINASE G ACTIVITY | CELL PATHWAYS, INC. (US) | 2000-10-10 | — | — | US | disclosed |
| EP-1038523-A2 | Method for identifying compounds for inhibition of neoplastic lesions | Cell Pathways, Inc. (US) | 2000-09-27 | — | — | EP | disclosed |
| EP-0997145-A1 | Methods for identifying compounds for inhibition of neoplastic lesions, and pharmaceutical compositions containing such compounds | Cell Pathways, Inc. (US) | 2000-05-03 | — | — | EP | disclosed |
| US-5858694-A | DETERMINING PHOSPHODIESTERASE AND CYCLOOXYGNEASE INHIBITORYACTIVITY IN A COMPOUND | CELL PATHWAYS, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0881300-A2 | Method for identifying compounds for inhibition of neoplastic lesions | Cell Pathways, Inc. (US) | 1998-12-02 | — | — | EP | disclosed |